



Marco de Morpurgo

Partner

GLOBAL CO-CHAIR, LIFE SCIENCES SECTOR

marco.demorpurgo@dlapiper.com

Rome

T: +39 06 68 880 1

F: +39 06 68 880 201

Marco de Morpurgo focuses on government regulation of the Life Sciences industry. He helps companies doing business in the EU navigate the complex regulatory structures governing the sector, counseling such clients on regulatory strategies and compliance matters.

His practice covers the regulation of pharmaceuticals, biotechnologies, medical devices, and other health-related regulated products in the EU. He provides strategic advice on a broad range of regulatory issues, including clinical trials, product approvals, market access, promotion and advertising, post-market obligations, as well as on industry-specific ethical and behavioral rules. Most of Marco's work is multi-jurisdictional and he has broad experience assisting clients manage regulatory divergence within the EU and globally.

He regularly speaks and writes on Life Sciences topics. He is a member of the Editorial Board of the European Pharmaceutical Law Review and teaches Life Sciences Law at HEC Paris.

- IP ja tehnologia

- Biotieteet

Italian englanti ranska
espanja

KIELITAITO

- Italian
- englanti
- ranska
- espanja

Professional Qualifications

- Avvocato admitted to the Rome Bar
- Avocat admitted to the Paris Bar
- Abogado registered with Ilustre Colegio de Abogados de Madrid

- Attorney-at-law admitted with the Supreme Court of New York

Kokemus

- Before joining DLA Piper, Marco worked with leading international law firms in Brussels, London and Paris.

Koulutus

- University of Milan, Ph.D., Comparative Law
- Harvard Law School, LL.M.
- IUC Turin, M.Sc., Comparative Law, Economics & Finance
- University of Trieste, Law degree

INSIGHTS

Publications

Embracing Digital Evolution: Our new business report

14 September 2021

Our new report - *Embracing Digital Evolution* - shows how businesses can succeed in Industry 4.0, with contributions from digital revolutionaries such as Microsoft, Salesforce, Rolls-Royce and DocuSign.

Digital Therapeutics - evolution and entry into mainstream healthcare

18 September 2020

Research undertaken by DLA Piper's Life Sciences sector in conjunction with The Lawyer seeks to understand the current developments in the field of digital therapeutics, looking at key questions that need to be addressed if these products are to become mainstream components of health systems across the world.

- EU SPC Manufacturing Waiver Becomes Effective: What Can Industry Expect?, *European Pharmaceutical Law Review*, Volume 3, Issue 3 (2019)
- The Sun Also Rises in Italy: New Statutory Transparency Requirements Expected under the Proposed Italian Sunshine Act, *European Pharmaceutical Law Review*, Volume 2, Issue 4 (2018)
- Italy Reforms Clinical Trial Rules, *European Pharmaceutical Law Review*, Volume 2, Issue 1 (2018)

UUTISET

DLA Piper advises Philip Morris International Inc. on USD16 billion recommended cash offer for Swedish Match

12 May 2022

DLA Piper, as International Counsel, is advising Philip Morris Holland Holdings B.V., an Affiliate of Philip Morris International Inc. (PMI), on its USD16 billion recommended public offer to the shareholders of Swedish Match AB (Swedish Match), a public limited company with shares listed on Nasdaq Stockholm.

DLA Piper advises Axsome Therapeutics in its acquisition of Sunosi from Jazz Pharmaceuticals

13 April 2022

DLA Piper represented Axsome Therapeutics in connection with its acquisition of Sunosi from Jazz Pharmaceuticals.

25 DLA Piper lawyers in 9 countries recognized as world's leading patent professionals

15 October 2020

IAM Patent 1000: The World's Leading Patent Professionals 2020 has named 25 DLA Piper lawyers in nine countries to its list of top patent professionals.
